Skip to Page Content
Top Groups:
hostvouchet
Shopping
General
International News
US Business
Leisure Lifestyles
Social Networking
Bookmarking
(more ยป)
Post Details
-
Tibotec Presents Interim Findings For TMC435
New clinical data show antiviral activity of TMC435, an investigational protease inhibitor (PI) being developed by Tibotec BVBA for the treatment of chronic hepatitis C virus (HCV) infection.
- Saved By: turk904
- Tags: presents , hepatitis , hepatitis c , pi , chronic hepatitis c , antiviral activity , bvba , genotype , hepatitis c treatment , hepatitis treatment , interim findings , investigational protease inhibitor , news today , and virus infection
- Group: (none)
post comments
[Add Comment]
Copyright ©2009 Searchles, Inc. All Rights Reserved
